Peptide questions · LL-37

LL-37 side effects: what studies and users report

Reviewed Evidence: EmergingPublished by PepVault

The side effects most commonly reported for LL-37 are injection site pain, redness and mild systemic inflammation; the library’s evidence on it includes controlled trials in people.

The library holds no separate safety note for LL-37.

What is commonly reported with LL-37

  • Injection site pain
  • Redness
  • Mild systemic inflammation

Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.

Each effect, and the other healing & recovery compounds the library lists it for
EffectAlso listed for (of 18)
Injection site painNone: listed for LL-37 alone
RednessNone: listed for LL-37 alone
Mild systemic inflammationNone: listed for LL-37 alone
A smiling man in a grey t-shirt in his living room, holding his phone

PepVault for iPhone

Track LL-37 in PepVault

Log each dose and any side effect beside it, so you can see what changed and when.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Which LL-37 side effects the healing & recovery group shares

Across the 19 healing & recovery compounds in the library, the effects listed most often are headache (7 of 19), injection site reaction (7 of 19), nausea (rare) (7 of 19) and fatigue (6 of 19). None of LL-37’s 3 listed effects appears for another healing & recovery compound: injection site pain, redness and mild systemic inflammation are its own in the library.

Where the LL-37 reports come from

The library rates the evidence on LL-37 as emerging: mostly preclinical, with limited human data.

Of the library’s 5 research notes on LL-37, 5 rest on community reports.

Our 6 study pages on LL-37: 3 randomized trials, 1 observational study, 1 cell study (human and murine macrophages) and 1 cell study (normal human keratinocytes).

So LL-37 has controlled trials in people to set its listed effects against.

What our LL-37 study pages report on safety

LL-37 taken by mouth shortened time to negative COVID-19 RNA test

Randomized trial, human, 2023: No severe side effects were seen during the hospital stay or follow-up. It measured how fast virus RNA cleared and safety, not other outcomes such as symptoms.

LL-37: no healing gain over placebo for venous leg ulcers overall

Randomized trial, human, 2021: Both strengths were well tolerated and safe.

Questions people ask

What are the side effects of LL-37?

The side effects most commonly reported for LL-37 are injection site pain, redness and mild systemic inflammation; the library’s evidence on it includes controlled trials in people.

Do LL-37’s side effects come from human studies?

The library rates the evidence on LL-37 as emerging, and the library’s evidence on it includes controlled trials in people.

Which LL-37 side effects are its own?

Among the healing & recovery compounds, the library lists injection site pain, redness and mild systemic inflammation for LL-37 alone.

More on LL-37

Track it in the app

PepVault for iPhone

Track LL-37 in PepVault

Log each dose and any side effect beside it, so you can see what changed and when.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo